基于新抗原的肿瘤个体化治疗研究与应用进展  

Application Progress and Research of Neoantigen-based Individualized Cancer Therapy

作　　者：韦树丽 胡茫莎 王苹莉[1] WEI Shuli;HU Mangsha;WANG Pingli(The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;不详)

机构地区：[1]浙江大学医学院附属第二医院,浙江杭州310009

出　　处：《中外医学研究》2022年第17期177-181,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：浙江省卫生健康重大科技计划项目(WKJ-ZJ-2122)。

摘　　要：新抗原是癌细胞通过非同义突变产生的可被加工提呈并引起特异性T细胞免疫应答的异常蛋白。新抗原的强大免疫原性及其仅表达于肿瘤细胞的特点,使其成为近些年肿瘤治疗的热门靶点。基于新抗原的个体化疫苗和靶向新抗原的过继细胞疗法在临床试验中取得了良好疗效,增强了免疫治疗的临床效果。本文将对近些年基于新抗原的肿瘤个体化治疗的最新研究和应用进展做一介绍。Neoantigen is an abnormal protein produced by cancer cells through nonsynonymous mutation,which can be processed and presented and cause specific T cell immune response.The strong immunogenicity of neoantigens and their only expression in tumor cells make them a hot target for tumor therapy in recent years.Individualized vaccine based on neoantigen and adoptive cell therapy targeting neoantigen have achieved good curative effect in clinical trials,and enhances the clinical effect of immunotherapy.This paper will introduce the latest research and application progress of tumor individualized therapy based on neoantigen in recent years.

关 键 词：新抗原 癌症 个体化疫苗 TIL CAR-T TCR-T 

分 类 号：R730.51[医药卫生—肿瘤]